Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism Read more →
Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug Read more →
Chutes & Ladders—Neumora shuffles leadership ahead of IND Read more →